北海康成(01228.HK)治療膠質母細胞瘤藥物之內地臨床試驗完成患者入組
北海康成(01228.HK)公布,CAN008(asunercept)治療膠質母細胞瘤在中國的II期臨床試驗現已完成患者入組,共有117名患者參與。
公司指,在3月份舉辦的ESMO肉瘤和罕見癌症年會上公布的CAN008第一期臨床試驗五年長期隨訪數據顯示,高劑量組患者總體生存率為67%,中位無進展生存期為17.95個月。公司預計CAN008在中國進行的II期GBM臨床試驗中期數據將於2023年中期公布。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.